Replies to post #1642 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

In the CC Dr. Stoll may tell us that Cortex effectively can't run any new trials (due to dosage restrictions) for the next 2-3 months.

And he may discuss the need for a financing before a BP deal.

That would be the opposite of what COR longs are hoping for, but realistic possibilities... Aiming4.